CN117384283A - 一种治疗晚期肿瘤的药物 - Google Patents
一种治疗晚期肿瘤的药物 Download PDFInfo
- Publication number
- CN117384283A CN117384283A CN202311356195.9A CN202311356195A CN117384283A CN 117384283 A CN117384283 A CN 117384283A CN 202311356195 A CN202311356195 A CN 202311356195A CN 117384283 A CN117384283 A CN 117384283A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- humanized
- antibody
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 22
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 229940079593 drug Drugs 0.000 title abstract description 4
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract description 3
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 239000013604 expression vector Substances 0.000 claims description 7
- 239000013612 plasmid Substances 0.000 claims description 7
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 5
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 3
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 3
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 3
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 3
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 3
- 201000001441 melanoma Diseases 0.000 claims description 3
- 201000002528 pancreatic cancer Diseases 0.000 claims description 3
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 3
- 208000032612 Glial tumor Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 201000006612 cervical squamous cell carcinoma Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 208000020816 lung neoplasm Diseases 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 8
- 238000004519 manufacturing process Methods 0.000 claims 2
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 abstract description 19
- 230000000694 effects Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000008499 blood brain barrier function Effects 0.000 abstract description 3
- 210000001218 blood-brain barrier Anatomy 0.000 abstract description 3
- 230000000149 penetrating effect Effects 0.000 abstract description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 10
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 10
- 150000001413 amino acids Chemical group 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 7
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 229950004003 fresolimumab Drugs 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- IVLXQGJVBGMLRR-UHFFFAOYSA-N 2-aminoacetic acid;hydron;chloride Chemical compound Cl.NCC(O)=O IVLXQGJVBGMLRR-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000012286 ELISA Assay Methods 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960001269 glycine hydrochloride Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000003259 recombinant expression Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 1
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 102000018120 Recombinases Human genes 0.000 description 1
- 108010091086 Recombinases Proteins 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 238000011091 antibody purification Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
本发明提供了一种治疗晚期肿瘤的药物，属于生物医药领域。该治疗晚期肿瘤的药物是以本发明的人源化纳米抗体为活性成分，加上要学上可接受的辅料制备而成的制剂。该人源化纳米抗体在保持与TGFβ亲和力的同时能阻断TGFβ与其受体的结合，并且最大程度的降低了异源性带来的免疫风险，更有利于穿透血脑屏障，更易到达肿瘤内部发挥治疗效果，在制备治疗晚期肿瘤的药物中具有广阔的应用前景。
Description
技术领域
本发明属于生物医药领域，具体涉及一种治疗晚期肿瘤的药物。
背景技术
恶性肿瘤发生过程中，会出现生长因子和细胞因子表达异常，其与肿瘤的发生和预后关系密切。转化生长因子(TGF)β是一个大的蛋白家族中的成员，包括结构和功能相似的3个成员:TGFβ1、TGFβ2和TGFβ3。体外试验表明这三个分子能够通过抑制cyclin-依赖性激酶诱导正常细胞和一些恶性转化的上皮细胞发生细胞生长周期停滞。TGFβ还可以通过失活突变、其相应受体的下调或TGFβ信号转导通路的元件突变起到生长抑制效应。研究表明在结直肠癌患者体内TGFβ1过表达，在正常细胞中不表达TGFβ1蛋白和mRNA；还有研究发现晚期胃癌患者标本的TGFβ2的表达水平提高，其与患者预后有明显相关。肿瘤发展至晚期TGFβ会呈现出促进肿瘤恶化的趋势。
因此，开发能够抑制TGFβ表达的药物对晚期肿瘤的治疗具有重要意义。
发明内容
本发明的目的在于提供一种抗TGFβ的人源化纳米抗体，以及以该抗TGFβ的人源化纳米抗体作为活性成分的抗肿瘤药物。
本发明提供了一种人源化纳米抗体，它包括互补决定区CDR1-CDR3，CDR1的氨基酸序列为FTFRLYN，CDR2的氨基酸序列为ITKAGQS，CDR3的氨基酸序列为AALHARFTY。
进一步地，所述人源化纳米抗体还包括与互补决定区CDR1-CDR3交替连接的四个框架区FR1-FR4，FR1的氨基酸序列为QVQLVESGGGLVQPGGSLRLSCAASG，FR2的氨基酸序列为LGWFRQAPGQEREAVAA，FR3的氨基酸序列为YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC，FR4的氨基酸序列为WGQGTLVTVSS。
进一步地，所述人源化纳米抗体的氨基酸序列为：
QVQLVESGGGLVQPGGSLRLSCAASGFTFRLYNLGWFRQAPGQEREAVAAI TKAGQSYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAALHARFTY WGQGTLVTVSS。
本发明还提供了一种制备上述人源化纳米抗体的方法，所述方法包括以下步骤：
(1)将核苷酸序列如SEQ ID NO:9所示的核苷酸分子连接至表达载体中获得阳性质粒；
(2)将阳性质粒转化宿主细胞，诱导表达人源化纳米抗体。
本发明还提供了一种核苷酸分子，它的核苷酸序列如SEQ ID NO:9所示。
本发明还提供了一种表达载体，它包含核苷酸序列如SEQ ID NO:9所示的核苷酸分子。
本发明还提供了一种宿主细胞，它包含上述的表达载体。
本发明还提供了一种治疗晚期肿瘤的药物，它是以上述人源化纳米抗体为活性成分，加上要学上可接受的辅料制备而成的制剂。
本发明还提供了上述人源化纳米抗体在制备治疗晚期肿瘤的药物中的用途。
进一步地，所述肿瘤为胃癌、胶质瘤、黑色素瘤、肾细胞癌、胰腺癌、乳腺癌、肺癌、前列腺癌、胆管癌、头颈部鳞状细胞癌或子宫颈癌。
本领域技术人员公知的，抗TGFβ抗体可以治疗的肿瘤包括：晚期胃癌、胶质瘤、恶性黑色素瘤、肾细胞癌、胰腺癌、乳腺癌、非小细胞肺癌、晚期前列腺癌、胆管癌、晚期头颈部鳞状细胞癌、晚期子宫颈癌等。
本发明的抗TGFβ人源化纳米抗体在保持与TGFβ亲和力的同时能阻断TGFβ与其受体的结合，在制备治疗晚期肿瘤的药物中具有广阔的应用前景。
本发明的抗TGFβ人源化纳米抗体分子量约15KDa，这种抗体是人源化抗体，其最大程度的降低了异源性带来的免疫风险，更有利于穿透血脑屏障，更易到达肿瘤内部发挥治疗效果。
显然，根据本发明的上述内容，按照本领域的普通技术知识和惯用手段，在不脱离本发明上述基本技术思想前提下，还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式，对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1.人源化纳米抗体与TGFβ1亲和力检测。
图2.人源化纳米抗体与TGFβ2亲和力检测。
图3.人源化纳米抗体与TGFβ3亲和力检测。
具体实施方式
本发明所用原料与设备均为已知产品，通过购买市售产品所得。
实施例1：人源化纳米抗体的制备
1.构建表达载体
(1)骨架载体酶切：工具载体pcDNA3.1-x-IgG1进行BamH I/EcoR I酶切，37℃双酶切5h后采用PCR产物回收试剂盒(Cycle-Pure Kit PCR产物纯化试剂盒OMEGA D6492-01)回收载体。
(2)同源重组：将用于重组表达的核苷酸片段使用ddH2O稀释20倍，取1ul稀释后的样品与上述酶切回收的载体进行同源重组(重组酶，NovoRec Plus one step PCR CloningKit近岸蛋白货号NR005-01B)。
用于重组表达的核苷酸片段的序列为：
TATGTTGTGTGGAATTGTGAGCGGATAACAATTGAATTCAGGAGGAATT
TAAAATGAAAAAGACAGCTATCGCGATTGCAGTGGCACTGGCTGGTTT
CGCTACCGTGGCCCAGGCGGCCCAGGTGCAGCTGGTTGAAAGTGGCG
GTGGCCTGGTGCAGCCGGGTGGTTCACTGCGTCTGAGTTGTGCCGCAA
GCGGTTTTACCTTTAGGCTGTATAATCTGGGCTGGTTTCGTCAGGCCCCT
GGTCAGGAACGCGAAGCAGTTGCAGCCATTACCAAAGCAGGTCAGAG
CTATTATGCAGATAGCGTTAAAGGCCGCTTTACCATTAGCCGCGATAATA
GCAAAAATACCCTGTATCTGCAGATGAATAGTCTGCGTGCCGAAGATAC
CGCAGTTTATTATTGTGCAGCGCTTCATGCTCGTTTTACCTATTGGGGTC
AGGGCACCCTGGTTACCGTTAGCAGTGCGCACCACAGCGAAGACCCCC
ATGGCCAGGCCGGCCAGCACCATCACCATCACCATGGCGCATACCCGTA
CGACGTTCCGGACTACGCTTCTTAGGAGGGTGGTGGCTCTGAGGGTGG
CGGTTCTGAGGGTGGCGGCTCTGAGGGAGGCGGTTCCGGTGGTGGCTC
TGGTTCCGGTGATTTTGATTATGAAAAGATGGCAAACGCTAATAAGGGG
GCTATGACCGAAAATGCCGATGAAAACGTGCTACAGTCTGACGCTAAA
GGCAAACTTGATTCTGTCGCTACTGATTACGGTGCTGCTATCGATGGTTT
CATTGGTGACGTTTCCGGCCTTGCTAATGGTAATGGTGCTACTGGTGATT
TTGCTGGCTCTAATTCCCAGATGGCTCAAGTCGGTGACGGTGATAATTC
ACCTTTAATGAATAATTTCCGTCAATATTTACCTTCCCTCCCTCAATCGGTTGAATG(SEQ ID NO:9)。
(3)大肠杆菌菌液PCR鉴定：从平板上挑取单克隆大肠杆菌菌落于200ul LB培养基37℃,220rpm培养3h，取1ul菌液作为模板，进行菌液PCR鉴定，选择鉴定的阳性克隆送去测序，将PCR产物电泳切角回收(Gel Extraction Kit胶回收试剂盒OMEGA，货号D2500-01)后，再次进行同源重组，菌液PCR鉴定后，选择鉴定的阳性克隆送去测序。
2.人源化纳米抗体Hek293F细胞表达与纯化
(1)抗体表达
将菌种接种到20ml含有氨苄青霉素的LB培养基中，37℃培养箱培养过夜，采用质粒提取试剂盒(Plasmid Miniprep Kit II，倍沃医学Cat:BW-PD1213)抽提质粒。传代Hek293细胞保持细胞良好生长状态，活率大于95％，转染时调整Hek293细胞密度为2.5×106cells/ml。取50ug表达质粒加入到1ml OPM培养基中混匀、取150ug PEI加入到1ml OPM培养基中混匀，上述两者混合后摇匀，室温静置30min后加入至50ml Hek293细胞中，于CO2摇床培养，第二天加入5％终体积的OPM培养基补料，继续培养至第7天，10000rmp离心20min收获细胞培养上清，用于蛋白纯化。
(2)抗体纯化
protein A重力柱纯化抗体蛋白：从冰箱中取出重力柱，用超纯水冲洗一个柱体积，0.1M NaOH冲洗一个柱体积，PBS缓冲液冲洗3个柱体积。
将离心后的细胞上清全部上样至重力柱，PBS缓冲液冲洗3个柱体积后，加入800ul的0.1M甘氨酸盐酸盐(Gly-HCl)洗脱，重复洗脱2次，收集目标蛋白(命名为RS27)，测定蛋白纯度不低于95％。
目标蛋白RS27的氨基酸序列如SEQ ID NO:8所示，它包括互补决定区CDR1-CDR3，互补决定区被四个框架区FR1、FR2、FR3和FR4所分隔。
表1.目标蛋白的氨基酸序列
以下通过实验例证明本发明人源化纳米抗体的活性。
实验例1：人源化纳米抗体与TGFβ1/2/3的亲和力检测
1.实验方法
TGFβ1/2/3抗原以1ug/ml浓度包被酶标板，人源化纳米抗体RS27从50ug/ml开始5倍比稀释后加入，采用anti-Fc二抗检测抗体与TGFβ1/2/3结合情况。以可同时靶向TGFβ1/2/3三种亚型的已知单克隆抗体Fresolimumab(非苏木单抗)作为对照抗体。
2.实验结果
亲和力ELISA试验结果如图1-3所示，可以看出，本发明RS27抗体能够同时靶向TGFβ1/2/3三种亚型。
本发明RS27抗体对TGFβ1的亲和力与对照抗体Fresolimumab相当(图1)，对TGFβ2的亲和力高于对照抗体Fresolimumab(图2)，对TGFβ3的亲和力高于对照抗体Fresolimumab(图3)。
实验例2：人源化纳米抗体对TGFβ1与TGFβR2阻断作用检测
1.实验方法
先用ELISA检测TGFβR2-FC-His与TGFβ1结合情况，选择合适浓度(该浓度处OD450以1左右为宜)的TGFβR2-FC-His作为与抗体竞争实验浓度。采用HRP标记的anti-His二抗检测，同时以50ul PBS和等体积的50ug/ml TGFβR2-FC-His做为对照，若实验组OD450明显弱于对照组，则可视为竞争。
2.实验结果
从竞争性ELISA试验结果可以看出，RS27抗体能够高效地阻断TGFβ1与其受体TGFβR2的结合(表2)。
表2.RS27对TGFβ1与TGFβR2结合的阻断作用
| 实验组 | OD值 |
| RS27 | 0.6354 |
| Fresolimumab | 0.5724 |
| PBS | 0.9194 |
综上，本发明提供了一种以人源化纳米抗体为活性成分的治疗晚期肿瘤的药物。该人源化纳米抗体在保持与TGFβ亲和力的同时能阻断TGFβ与其受体的结合，并且最大程度的降低了异源性带来的免疫风险，更有利于穿透血脑屏障，更易到达肿瘤内部发挥治疗效果，在制备治疗晚期肿瘤的药物中具有广阔的应用前景。
Claims (10)
1.一种人源化纳米抗体，其特征在于，它包括互补决定区CDR1-CDR3，CDR1的氨基酸序列为FTFRLYN，CDR2的氨基酸序列为ITKAGQS，CDR3的氨基酸序列为AALHARFTY。
2.根据权利要求1所述的人源化纳米抗体，其特征在于，它还包括与互补决定区CDR1-CDR3交替连接的四个框架区FR1-FR4，FR1的氨基酸序列为QVQLVESGGGLVQPGGSLRLSCAASG，FR2的氨基酸序列为LGWFRQAPGQEREAVAA，FR3的氨基酸序列为YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC，FR4的氨基酸序列为WGQGTLVTVSS。
3.根据权利要求2所述的人源化纳米抗体，其特征在于，它的氨基酸序列为：
QVQLVESGGGLVQPGGSLRLSCAASGFTFRLYNLGWFRQAPGQEREAVAAI TKAGQSYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAALHARFTY WGQGTLVTVSS。
4.一种制备权利要求1-3任一项所述人源化纳米抗体的方法，其特征在于，所述方法包括以下步骤：
(1)将核苷酸序列如SEQ ID NO:9所示的核苷酸分子连接至表达载体中获得阳性质粒；
(2)将阳性质粒转化宿主细胞，诱导表达人源化纳米抗体。
5.一种核苷酸分子，其特征在于，它的核苷酸序列如SEQ ID NO:9所示。
6.一种表达载体，其特征在于，它包含权利要求5所述的核苷酸分子。
7.一种宿主细胞，其特征在于，它包含权利要求6所述的表达载体。
8.一种治疗晚期肿瘤的药物，其特征在于，它是以权利要求1-3任一项所述人源化纳米抗体为活性成分，加上要学上可接受的辅料制备而成的制剂。
9.权利要求1-3任一项所述人源化纳米抗体在制备治疗晚期肿瘤的药物中的用途。
10.根据权利要求9所述的用途，其特征在于，所述肿瘤为胃癌、胶质瘤、黑色素瘤、肾细胞癌、胰腺癌、乳腺癌、肺癌、前列腺癌、胆管癌、头颈部鳞状细胞癌或子宫颈癌。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311356195.9A CN117384283A (zh) | 2023-10-17 | 2023-10-17 | 一种治疗晚期肿瘤的药物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311356195.9A CN117384283A (zh) | 2023-10-17 | 2023-10-17 | 一种治疗晚期肿瘤的药物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117384283A true CN117384283A (zh) | 2024-01-12 |
Family
ID=89462512
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311356195.9A Pending CN117384283A (zh) | 2023-10-17 | 2023-10-17 | 一种治疗晚期肿瘤的药物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117384283A (zh) |
-
2023
- 2023-10-17 CN CN202311356195.9A patent/CN117384283A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2018036473A1 (zh) | 抗ctla4-抗pd-1双功能抗体、其药物组合物及其用途 | |
| CN116514971B (zh) | 一种抗lag-3的单克隆抗体、其抗原结合片段及其应用 | |
| CN110938144B (zh) | 一种抗angptl3单克隆抗体及其在制备治疗肾病综合征药物中的用途 | |
| US20210070875A1 (en) | Anti-c5ar antibody and preparation method and use thereof | |
| CN108635579B (zh) | 抗人bFGF纳米抗体在制备治疗黑色素瘤药物中的应用 | |
| US20220396615A1 (en) | Anti-human il6 monoclonal antibodies, preparation method therefor and use thereof | |
| CN115038718B (zh) | 抗人程序性死亡配体-1（pd-l1）的抗体及其用途 | |
| US20210246220A1 (en) | Anti-BCMA single-chain antibody scFv and preparation method and application thereof | |
| CN113105546B (zh) | 一种抗重组人碱性成纤维细胞生长因子纳米抗体及其应用 | |
| CN111393525A (zh) | 一种AP-2alpha的单克隆抗体及用于制备治疗宫颈癌的药物中的用途 | |
| CN113698493B (zh) | 一种针对VEGF和TGF-β的双功能蛋白及其应用 | |
| CN114057880B (zh) | 一种dll3单克隆抗体 | |
| CN117384283A (zh) | 一种治疗晚期肿瘤的药物 | |
| CN117305314A (zh) | 一种人源化纳米抗体及其在制备治疗晚期肿瘤的药物中的用途 | |
| CN117343172A (zh) | 一种抗TGFβ的人源化纳米抗体及其制备方法 | |
| CN117209602A (zh) | 一种人源化纳米抗体及其在制备TGFβ抑制剂中的用途 | |
| CN117106082A (zh) | 一种抗TGFβ的人源化纳米抗体 | |
| CN117126858A (zh) | 一种用于预防和/或治疗肿瘤的抗TGFβ的人源化纳米抗体 | |
| CN117448338A (zh) | 一种治疗晚期肿瘤和纤维化疾病的药物 | |
| CN113185597A (zh) | 一种可激活患者的抗肿瘤免疫反应的人肿瘤抗原及其应用 | |
| CN110563841A (zh) | 一种人源化抗Grb2单克隆抗体、及其制备方法和应用 | |
| CN117069839A (zh) | 一种抗TGFβ抗体及其制备方法和用途 | |
| CN117230078A (zh) | 一种抗TGFβ的人源化纳米抗体及其制备方法和用途 | |
| CN112513084A (zh) | 人源化抗人ctla4单克隆抗体及其制备方法和用途 | |
| CN117417444A (zh) | 一种治疗纤维化疾病的人源化纳米抗体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |